Heartseed
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Japanese biotech developing iPSC-derived cardiomyocyte transplantation therapies to remuscularize the heart and treat severe heart failure.
Cardiovascular
Technology Platform
A proprietary, integrated platform for generating, purifying, and transplanting ventricular-specific cardiomyocyte spheroids ('Heartseeds') from induced pluripotent stem cells (iPSCs) for cardiac remuscularization.
Opportunities
Addressing the massive, unmet global need in heart failure with a potentially curative cellular therapy that could reduce dependency on heart transplants and mechanical devices, with a platform extendable to autologous and hypoimmunogenic next-generation cell products.
Risk Factors
Clinical risks include demonstrating safety (particularly arrhythmogenic and tumorigenic potential), efficacy, and long-term engraftment of transplanted cells in a first-in-human trial, alongside complex manufacturing, scalability, and eventual reimbursement challenges for a novel regenerative therapy.
Competitive Landscape
Competes in the emerging field of iPSC-derived cardiomyocyte transplantation for heart failure; key differentiation lies in its ventricle-specific cell production, metabolic purification to remove undifferentiated cells, and spheroid-based ('Heartseed') delivery system designed for superior engraftment and functional integration.